---
title: "H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294794759.md"
description: "H.C. Wainwright analyst Ramakanth reiterated a Buy rating on Compugen (CGEN) with a $4.00 price target, noting the stock closed at $2.38. The analyst consensus remains a Strong Buy with an average target of $5.00. Additionally, Lake Street reaffirmed a Buy rating with a $6.00 target."
datetime: "2026-08-04T08:57:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294794759.md)
  - [en](https://longbridge.com/en/news/294794759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294794759.md)
---

# H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)

In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Compugen, with a price target of $4.00. The company’s shares closed yesterday at $2.38.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Ramakanth is a 5-star analyst with an average return of 17.8% and a 44.40% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Precigen, and MindWalk Holdings.

Currently, the analyst consensus on Compugen is a Strong Buy with an average price target of $5.00, which is an 110.08% upside from current levels. In a report released on July 21, Lake Street also reiterated a Buy rating on the stock with a $6.00 price target.

### Related Stocks

- [CGEN.US](https://longbridge.com/en/quote/CGEN.US.md)
- [MIRM.US](https://longbridge.com/en/quote/MIRM.US.md)
- [PGEN.US](https://longbridge.com/en/quote/PGEN.US.md)
- [HYFT.US](https://longbridge.com/en/quote/HYFT.US.md)

## Related News & Research

- [Compugen announces annual shareholder meeting](https://longbridge.com/en/news/294715709.md)
- [Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline](https://longbridge.com/en/news/294684055.md)
- [Amadeus IT Group: Operational Resilience and Margin Outperformance Support Unchanged $60 Price Target and Buy Rating](https://longbridge.com/en/news/294469810.md)
- [KBW Reaffirms Their Buy Rating on KKR & Co (KKR)](https://longbridge.com/en/news/294505673.md)
- [Ipsen: Strong Execution and Raised 2026 Guidance Support Buy Rating; €235 Price Target Reiterated](https://longbridge.com/en/news/294501268.md)